Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.
Pediatr Blood Cancer
; 60(6): 1022-6, 2013 Jun.
Article
em En
| MEDLINE
| ID: mdl-23255213
ABSTRACT
In the US, approximately 2,500 children are diagnosed annually with brain tumors. Their survival ranges from >90% to <10%. For children with medulloblastoma, the most common malignant brain tumor, 5-year survival ranges from >80% (standard-risk) to 60% (high-risk). For those with high-grade gliomas (HGGs) including diffuse intrinsic pontine gliomas, 5-year survival remains <10%. Sixty-five percent patients with ependymoma are cured after surgery and radiation therapy depending on the degree of resection and histopathology of the tumor. Phase II trials for brain tumors will investigate agents that act on cMET, PDGFRA, or EZH2 in HGG, DIPG, or medulloblastoma, respectively. Phase III trials will explore risk-based therapy stratification guided by molecular and clinical traits of children with medulloblastoma or ependymoma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ensaios Clínicos como Assunto
/
Neoplasias do Sistema Nervoso Central
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article